{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=The+TIMI+Study+Group",
    "query": {
      "sponsor": "The TIMI Study Group"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=The+TIMI+Study+Group&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T04:04:23.652Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01730534",
      "title": "Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent",
        "High Risk for Cardiovascular Event"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 17190,
      "start_date": "2013-04-25",
      "completion_date": "2018-09-11",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 234,
      "location_summary": "Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730534"
    },
    {
      "nct_id": "NCT00781391",
      "title": "Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke",
        "Atrial Fibrillation",
        "Embolism"
      ],
      "interventions": [
        {
          "name": "warfarin tablets",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban tablets (high dose regimen-60mg)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban tablets (low dose regimen-30mg)",
          "type": "DRUG"
        },
        {
          "name": "placebo warfarin",
          "type": "DRUG"
        },
        {
          "name": "placebo edoxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 21105,
      "start_date": "2008-11",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 316,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Lake Havasu City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00781391"
    },
    {
      "nct_id": "NCT00116012",
      "title": "Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "rNAPc2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ARCA Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 300,
      "start_date": "2005-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-11-29",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116012"
    },
    {
      "nct_id": "NCT00409578",
      "title": "Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Acute Coronary Syndrome",
        "Myocardial Ischemia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aliskiren 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 320 mg",
          "type": "DRUG"
        },
        {
          "name": "Aliskiren/valsartan 300/320 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1101,
      "start_date": "2007-02",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2011-04-19",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 1,
      "location_summary": "Investigative Site, New Jersey",
      "locations": [
        {
          "city": "Investigative Site",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00409578"
    },
    {
      "nct_id": "NCT07028749",
      "title": "Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "MAR001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 316,
      "start_date": "2025-06-30",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 26,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 23 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07028749"
    },
    {
      "nct_id": "NCT04516291",
      "title": "A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "Hyperlipidemias",
        "Hyperlipoproteinemias"
      ],
      "interventions": [
        {
          "name": "Vupanorsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2020-09-28",
      "completion_date": "2021-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 59,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lincoln",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04516291"
    },
    {
      "nct_id": "NCT02019264",
      "title": "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Disease",
        "High Cardiovascular Risk",
        "Obesity",
        "Overweight",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lorcaserin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 14673,
      "start_date": "2014-01-24",
      "completion_date": "2018-05-14",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 373,
      "location_summary": "Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019264"
    },
    {
      "nct_id": "NCT00099788",
      "title": "Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myocardial Ischemia"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6560,
      "start_date": "2004-10",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2009-11-26",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099788"
    },
    {
      "nct_id": "NCT02145468",
      "title": "A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Losmapimod 7.5 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo twice daily",
          "type": "DRUG"
        },
        {
          "name": "Standard therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 3503,
      "start_date": "2014-06-03",
      "completion_date": "2015-12-14",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 91,
      "location_summary": "Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Cottonwood",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145468"
    },
    {
      "nct_id": "NCT04409834",
      "title": "Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19",
        "Venous Thromboembolism",
        "Arterial Thrombosis"
      ],
      "interventions": [
        {
          "name": "Unfractionated Heparin IV",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Unfractionated heparin SC",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin 40 mg SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The TIMI Study Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2020-08-05",
      "completion_date": "2022-03-10",
      "has_results": true,
      "last_update_posted_date": "2024-01-19",
      "last_synced_at": "2026-09-28T04:04:23.652Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409834"
    }
  ]
}